CIMC Safeway released its 1H26 results: 1H26 revenue was RMB1,456mn (+19.96% YoY), attributable NP was RMB45mn (-27.79% YoY), and recurring attributable NP was RMB41mn (-3.32% YoY). 2Q26 revenue was RMB899mn (+49.21% YoY, +61.33% QoQ), and attributable NP was RMB22mn (-44.20% YoY, -1.38% QoQ). The YoY revenue growth in 1H26 was driven by recovering tank container demand, which boosted orders, production, and sales volume, while the YoY decline in attributable NP was owing to lower gross margin amid intensified competition in the tank container market. By segment, 1H26 revenue from tank containers, medical equipment components, and the aftermarket business all recorded YoY growth. 1) 1H26 tank container revenue was RMB1,083mn (+17.20% YoY), driven by recovering tank container market demand, which boosted orders, production, and sales volume; 2) 1H26 medical equipment component revenue was RMB143mn (+19.89% YoY), maintaining rapid growth momentum; 3) 1H26 aftermarket business revenue was RMB80mn (+6.81% YoY), with the service network continuing to be optimized and incremental contributions from full-lifecycle services emerging. We are optimistic that the company, as a global leader in tank container manufacturing, will be among the first to benefit from the industry recovery, while the medical equipment components business continues to boast potential to be a second growth driver. Maintain OVERWEIGHT.
Considering ongoing uncertainty in downstream customer delivery schedules and pressure on profitability in 1H26, we lower our 2026/2027/2028 attributable NP forecasts to RMB263/383/514mn (previous: RMB317/445/525mn, down 17/14/2%), corresponding to BVPS of RMB7.88/8.02/8.37. The average 2026E PB of comparable companies on iFind consensus is 1.6x. Considering the high YoY growth in newly signed orders and orders on hand in 1H26, the formation of a second growth curve in the medical equipment components business, but also intense industry competition and a somewhat delayed pace of overall earnings recovery, we lower our premium and assign the company a 2026E PB of 1.8x, with a target price of RMB14.18 (previous: RMB17.91, on 2.2x 2026E PB).

　　事件描述
　　公司发布2026年半年报，实现营收14.56亿元，同增19.96%；实现归母净利润0.45亿元，同减27.79%；实现扣非归母净利润0.41亿元，同减3.32%。其中，单Q2公司实现营收8.99亿元，同增49.21%；实现归母净利润0.22亿元，同减44.20%；实现扣非归母净利润0.20亿元，同减11.52%。
　　事件点评
　　各产品收入均实现较快增长。分产品来看，标准不锈钢液体罐箱、特种不锈钢液体罐箱、碳钢罐箱、医疗设备部件分别实现营业收入6.50、3.43、0.90、1.43亿元，同比增速分别为14.99%、17.28%、35.69%、19.89%。
　　毛利率、费用率均有所下降。2026H1公司毛利率同减2.39pct至12.07%。费用率方面，2026H1公司期间费用率同减1.92pct至6.95%，其中销售费用率同减0.23pct至0.60%，管理费用率同减1.34pct至3.19%，财务费用率同增0.22pct至-0.17%，研发费用率同减0.57pct至3.33%。
　　化工终端用户需求有所恢复，新签订单同比大幅增长。2026年以来，中国化工终端用户需求有所恢复，推动中国化工物流运营商需求增长，罐箱市场需求回暖。公司持续深耕罐箱制造，积极培育壮大新市场，如做大做强氟化工、电解液、电子级化学品罐箱等，增强竞争优势。2026H1,公司累计新签订单16.65亿元，同增54.25%；截至2026年6月底，公司在手订单15.70亿元，同增86.81%。
　　医疗设备部件业务稳步推进产能建设，打造第二成长曲线。公司将以精密制造为基础，围绕客户需求，稳步推进产能建设，全面提升自动化、数字化水平和稳定交付能力；通过内部孵化、产业合作与外延并购等多元化路径，推动业务向附加值更高的医疗装备核心零部件环节延伸，进一步融入全球优质客户供应链体系。
　　盈利预测与估值
　　预计公司2026-2028年营收分别为30.59、36.79、41.54亿元，同比增速分别为28.02%、20.27%、12.91%；归母净利润分别为1.51、2.25、3.00亿元，同比增速分别为33.83%、49.33%、33.23%。公司2026-2028年业绩对应PE估值分别为52.06、34.86、26.17，维持“增持”评级。
　　风险提示
　　市场景气度不及预期风险；盈利能力恢复不及预期风险；新业务开拓不及预期风险等。

　　中集环科发布半年报，26H1实现营收14.56亿元，同比+19.96%，归母净利0.45亿元，同比-27.79%，扣非归母净利0.41亿元，同比-3.32%。其中26Q2实现营收8.99亿元，同比/环比+49.21%/+61.33%，归母净利0.22亿元，同比/环比-44.20%/-1.38%。公司26H1营收同比增长主要系罐箱需求回升带动订单及产销量增长，归母净利同比下滑或主要系罐箱市场竞争加剧态势下的毛利率下降。分业务来看，公司26H1罐箱、医疗设备部件、后市场业务营业收入均实现同比增长。1）26H1公司罐式集装箱营业收入10.83亿元，同比+17.20%，主要系罐箱市场需求回暖带动订单及产销量增长；2）26H1公司医疗设备部件营业收入1.43亿元，同比+19.89%，保持较快增长态势；3）26H1后市场业务营业收入0.80亿元，同比+6.81%，服务网络持续优化，全生命周期服务增量逐步显现。我们看好公司作为全球罐箱制造龙头率先受益于行业复苏，同时医疗设备部件第二引擎持续培育。维持“增持”评级。
　　26H1毛利率同比下降，期间费用率管控有所优化
　　26H1公司毛利率12.07%，同比-2.39pp；26Q2公司毛利率11.07%，同比/环比-3.30pp/-2.63pp，主要系罐箱需求虽有回升，但处于行业景气修复初期，整体市场竞争仍较为激烈。26H1公司期间费用率6.95%，同比-1.92pp。其中销售费用率0.60%，同比-0.23pp；管理费用率3.19%，同比-1.34pp；研发费用率3.33%，同比-0.57pp；财务费用率-0.17%，同比+0.22pp。公司期间费用率同比下降，主要系收入规模回升带动总体费用摊薄所致。
　　新签及在手订单同比高增，多式联运试点与高端介质打开空间
　　2026年以来中国化工终端用户需求有所恢复，推动中国化工物流运营商需求增长，中国化工产品价格指数由2025年末的3,930回升至26年6月底的4,511，涨幅约14.78%。此外，算力芯片规模化量产推高电子化学品使用需求，公司围绕半导体、新能源、氟化工赛道持续研发适配罐箱，26H1无水氟化氢（AHF）罐箱通过EXSIF及终端客户ORBIA检验。从订单角度看，26H1公司累计新签订单16.65亿元，同比+54.25%；截至6月底在手订单15.70亿元，同比+86.81%，在手订单储备有望为后续业绩提供支撑。
　　医疗设备部件毛利率逆势提升，持续推进品类扩张
　　26H1公司医疗设备部件业务毛利率44.62%，同比+1.64pp。随着医疗设备部件市场需求持续扩容，公司高端医疗影像设备关键零部件的研发与制造能力不断提升，产品范围逐步扩大，客户基础日益丰富。依托压力容器与精密加工领域的技术积累，公司产品能够适配磁共振影像等设备对低温、真空、高压等严苛工况的要求，已实现从供应商到战略合作伙伴的升级。展望未来，公司一方面通过内部挖潜提升产能并推进产能扩张规划，另一方面拓展客户群体与产品种类，医疗设备业务持续向好有望为公司业绩带来积极贡献。
　　盈利预测与估值
　　考虑到下游客户提货节奏仍存不确定性，上半年盈利端承压，我们下调公司2026-2028年归母净利润预测至2.63/3.83/5.14亿元（前值3.17/4.45/5.25亿元，分别下调17%/14%/2%），对应BPS为7.88/8.02/8.37元。可比公司2026年iFind一致预期PB均值为1.6倍，考虑到公司26H1新签及在手订单同比高增，医疗设备部件业务第二曲线逐步成型，但行业竞争较为激烈，整体业绩复苏节奏有所延后，我们下调溢价率，给予公司2026年1.8倍PB估值，目标价14.18元（前值17.91元，对应26年2.2倍PB）。
　　风险提示：汇率波动风险，化工物流行业复苏不及预期，原材料价格波动。

CIMC Safeway has reported 1Q26 revenue of RMB557mn(-8.86%YoY,-12.82%QoQ)and an attributable net profit of RMB23mn(+1.70%YoY,+72.91%QoQ).We attribute the YoY and QoQ declines in 1Q26 revenue to soft tank container product prices and fluctuations in downstream customer delivery schedules.On the bright side,attributable NP improved on both aYoY and QoQ basis,driven by the company's cost cutting and efficiency gains in production,as well as more optimized expense control overall.Maintain OVERWEIGHT.
Tank container business strained
By segment,the company's 1Q26 business decline was mainly affected by the tank container business,while the medical equipment components business and aftermarket business enjoyed steady growth.1)In 1Q26,tank container revenue of RMB387mn was down-19.48%YoY due to intense industry competition that pushed down tank container prices and caused fluctuations in the delivery schedules of downstream customer orders.2)In 1Q26,medical equipment component revenue of RMB67mn(+22.67%YoY)maintained rapid growth momentum.3)In 1Q26,aftermarket business revenue was RMB39mn,up+9.40%YoY.
1Q26 GPM improved QoQ;financial expense ratio optimized
In 1Q26,the company's GPM was 13.70%(-0.86pp YoY,+1.18pp QoQ).Although GPM declined YoY due to tepid demand and intensified competition in the tank container industry,the company achieved QoQ improvement in GPM through lean production and strengthened cost control.In 1Q26,the overall expense ratio was 7.22%(-0.86pp YoY,-2.93pp QoQ).Specifically,the sales expense ratio was 0.76%(-0.06pp YoY,+0.05pp QoQ),the administrative expense ratio was 4.24%(-0.44pp YoY,+0.52pp QoQ),the R&D expense ratio was 3.80%(+0.20pp YoY,+0.29pp QoQ),and the financial expense ratio was 1.57%(-0.57pp YoY,-3.79pp QoQ).We blame YoY and QoQ declines in the overall expense ratio on enhanced forex management and optimization of the financial expense ratio.
Earnings forecasts and valuation
We maintain our 2026/2027/2028 attributable net profit forecast at RMB317/445/525mn,translating to BVPS of RMB8.14/8.38/8.76.The average 2026E PB of comparable companies on iFind consensus is 1.8x.Considering the positive order trend in the company's tank container business in 1Q26 and its position as aglobal leader in tank container manufacturing,which stands to benefit first in the event of an industry recovery,we maintain our valuation of 2.2x 2026E PB and retain our target price of RMB17.91.

　　中集环科发布一季报，2026年一季度实现营收5.57亿元，同比/环比-8.86%/-12.82%，归母净利0.23亿元，同比/环比+1.70%/+72.91%。公司26Q1营收同环比下滑或主要系罐箱产品价格承压以及下游客户提货节奏波动所致，但归母净利润同环比均有所改善，主要系公司加强生产端降本增效，优化费用管控所致。维持“增持”评级。
　　罐箱业务仍相对承压，医疗与后市场业务稳步向上
　　分业务来看，公司26Q1业务下滑主要受罐箱业务影响，医疗设备部件业务与后市场业务稳步向上。1）26Q1公司罐式集装箱营业收入3.87亿元，同比-19.48%。主要系行业竞争加剧罐箱价格下滑，以及下游客户订单交付节奏波动影响。2）26Q1公司医疗设备部件营业收入0.67亿元，同比+22.67%，保持较快增长态势；3）26Q1后市场业务营业收入0.39亿元，同比+9.40%。
　　26Q1毛利率环比改善，财务费用率管控有所优化
　　26Q1公司毛利率13.70%，同比-0.86pp、环比+1.18pp。虽然由于罐箱行业需求承压、竞争加剧，公司毛利率同比下降，但通过精益生产和加强成本控制，公司毛利率实现环比改善。26Q1公司期间费用率7.22%，同比-0.86pp、环比-2.93pp。其中销售费用率0.76%，同比-0.06pp、环比+0.05pp；管理费用率4.24%，同比-0.44pp、环比+0.52pp；研发费用率3.80%，同比+0.20pp、环比+0.29pp；财务费用率1.57%，同比-0.57pp、环比-3.79pp。公司期间费率同环比均下降，主要系汇兑管理加强、财务费用率优化所致。
　　罐箱订单数据展现向好迹象，公司全面推进多元创新与降本增效
　　随着全球供应链格局向区域化、短链化、多元化转变，罐箱市场需求中枢有望持续提升，并不断向更智能、安全的绿色物流模式迈进。从订单角度看,公司罐式集装箱业务近期有向好迹象：26Q1公司新签订单9.79亿元，同比+120.18%；截至3月底在手订单17.27亿元，同比+118.32%，下游租赁商新签订单明显回升。公司不断通过智能化、数字化改革巩固行业地位，在手订单储备有望为后续业绩提供一定支撑。
　　医疗设备部件制造能力不断提升，产能扩张与产品拓展并举
　　随着医疗设备部件市场需求持续扩容，公司高端医疗影像设备关键零部件的研发与制造能力稳步提升，产品矩阵逐步拓宽，客户结构日趋多元。依托压力容器与精密加工领域的核心技术积累，公司在低温、真空、高压等严苛工况下的产品适配能力突出，性能表现获行业头部客户认可，订单粘性较强。展望未来，公司一方面将扩张现有产品产能，提升产线自动化水平；另一方面将积极拓展其他产品研发，公司医疗设备部件业务发展的持续向好有望为公司整体业绩带来积极贡献。
　　盈利预测与估值
　　我们维持公司2026-2028年归母净利润预测为3.17亿元、4.45亿元、5.25亿元，对应BPS为8.14、8.38、8.76元。可比公司2026年iFind一致预期PB均值为1.8倍，考虑到公司罐箱业务Q1订单趋势向好，作为全球罐箱制造龙头有望率先受益于行业复苏，我们维持给予公司2026年2.2倍PB估值，维持目标价17.91元。
　　风险提示：汇率波动风险，化工物流行业复苏不及预期，原材料价格波动。